/

/

专访：糖脂抗原提呈CD1d及NKT细胞活化治疗潜力

JoVE Journal
Biology

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Biology

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Please note that all translations are automatically generated. Click here for the English version.

专访：糖脂抗原提呈CD1d及NKT细胞活化治疗潜力

DOI:

•

18:08 min

•

December 31, 2007

•

Mitchell Kronenberg

¹Department of Developmental Immunology,La Jolla Institute for Allergy and Immunology

Chapters

00:00Introduction
00:44Physiological Role of CD1
04:52CD1d Tetramers
06:57Use of CD1d Tetramers in the Lab
08:46CD1d Tetramer Generation
11:40Therapeutic Utility of NKT Cells
14:43Mucosal Immunity
16:13Future of Immunology

Summary

Automatic Translation

自然杀伤T细胞（NKT），癌症autioimmunity监管，清除感染，并发展artheriosclerotic斑块的免疫反应的关键因素。在这次采访中，米奇Kronenberg讨论他的实验室的努力去了解通过糖脂抗原激活NKT细胞的机制。

Tags

Glycolipid Antigen Presentation CD1d NKT Cell Activation Immune Response Cancer Therapy Autoimmune Disease Regulation Infectious Agent Clearance Artheriosclerotic Plaques Glycolipid-reactive T Cells CD1d Tetramer Technology Therapeutic Agents Clinical Trials Immunology Field

Article

Embed

ADD TO PLAYLIST

Usage Statistics

Related Videos

克里斯托弗休斯：在体外血管生成的研究模型（面试）

调查白蚁后肠中的微生物的社区 - 面试

微生物群落，在自然和实验室 - 面试

使用微流体的细菌的趋化作用的研究 - 访

微生物群落的生物 - 面试

调节性T细胞治疗移植排斥反应和I型糖尿病的治疗潜力

专访：蛋白质折叠与神经退行性疾病的研究

专访：干细胞研究的生物反应器和三维支架材料表面改性

专访：HIV - 1前病毒DNA切除使用一个演进的重组酶

激活细胞凋亡的细胞色素的细胞质显微注射 C</em

Read Article

JoVE

Privacy  •  Terms of Use  •  Policies

Share on Twitter

Share on Facebook

Share on LinkedIn

Share on Wechat

Contact Us

Recommend to library

JoVE NEWSLETTERS

RESEARCH

JoVE Journal

Methods Collections

JoVE Encyclopedia of Experiments

Archive

EDUCATION

JoVE Core

JoVE Business

JoVE Science Education

JoVE Lab Manual

Faculty Resource Center

Faculty Site

Authors

Overview

Publishing Process

Editorial Board

Scope and Policies

Peer Review

FAQ

Submit

Librarians

Overview

Testimonials

Subscriptions

Access

Resources

Library Advisory Board

FAQ

ABOUT JoVE

Overview

Leadership

Blog

JoVE

Privacy  •  Terms of Use  •  Policies

Share on Twitter

Share on Facebook

Share on LinkedIn

Share on Wechat

Contact Us

Recommend to library

JoVE NEWSLETTERS

RESEARCH

JoVE Journal

Methods Collections

JoVE Encyclopedia of Experiments

Archive

EDUCATION

JoVE Core

JoVE Business

JoVE Science Education

JoVE Lab Manual

Faculty Resource Center

Faculty Site

Authors

Overview

Publishing Process

Editorial Board

Scope and Policies

Peer Review

FAQ

Submit

Librarians

Overview

Testimonials

Subscriptions

Access

Resources

Library Advisory Board

FAQ

ABOUT JoVE

Overview

Leadership

Blog

RESEARCH

JoVE Journal

Methods Collections

JoVE Encyclopedia of Experiments

Archive

EDUCATION

JoVE Core

JoVE Business

JoVE Science Education

JoVE Lab Manual

Faculty Resource Center

Faculty Site

Authors

Overview

Publishing Process

Editorial Board

Scope and Policies

Peer Review

FAQ

Submit

Librarians

Overview

Testimonials

Subscriptions

Access

Resources

Library Advisory Board

FAQ

ABOUT JoVE

Overview

Leadership

Blog

JoVE

Privacy  •  Terms of Use  •  Policies

Share on Twitter

Share on Facebook

Share on LinkedIn

Share on Wechat

Contact Us

Recommend to library

JoVE NEWSLETTERS

Browse...

Research

Education

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Authors

Overview Publishing Process Editorial Board Scope and Policies Peer Review FAQ Submit

Librarians

Overview Testimonials Subscriptions Access Resources Library Advisory Board FAQ

ABOUT JoVE

Overview Leadership Blog

Share on Twitter

Share on Facebook

Share on LinkedIn

Share on Wechat

Contact Us

Recommend to library

JoVE NEWSLETTERS

Privacy

.

Terms of Use

.

Policies

Copyright © 2024 MyJoVE Corporation. All rights reserved

Copyright © 2024 MyJoVE Corporation. All rights reserved

-1::1